60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60P successfully achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60P also collaborates with prominent research organizations in the U.S., Australia, and Singapore. 60P’s mission has been supported through in-kind funding from the DOD and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60P is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.
Company profile
Ticker
SXTP
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
452406880
SXTP stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
1 Apr 24
8-K
Other Events
14 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Feb 24
8-K
Entry into a Material Definitive Agreement
20 Feb 24
8-K
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
2 Feb 24
424B4
Prospectus supplement with pricing info
31 Jan 24
EFFECT
Notice of effectiveness
30 Jan 24
CORRESP
Correspondence with SEC
26 Jan 24
CORRESP
Correspondence with SEC
26 Jan 24
CORRESP
Correspondence with SEC
26 Jan 24
Latest ownership filings
4
Change in insider ownership
3 Apr 24
4
GEOFFREY S DOW
2 Feb 24
4
CHERYL XU
2 Feb 24
SC 13G
KNIGHT THERAPEUTICS INTERNATIONAL SA
18 Dec 23
3
Initial statement of insider ownership
18 Dec 23
4
TYRONE MILLER
12 Jul 23
4
GEOFFREY S DOW
12 Jul 23
3
CHERYL XU
11 Jul 23
3
PAUL FIELD
11 Jul 23
3
STEPHEN TOOVEY
11 Jul 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q3 2023
9.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 1.11 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Knight Therapeutics | 1.11 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Feb 24 | Cheryl Xu | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,000 | 0.00 | 6,000 |
31 Jan 24 | Geoffrey S Dow | Common Stock | Buy | Acquire P | No | No | 0.375 | 25,974 | 9.74 k | 703,599 |
31 Jan 24 | Geoffrey S Dow | Warrant Common Stock | Buy | Acquire P | No | No | 0.01 | 25,974 | 259.74 | 25,974 |
31 Jan 24 | Cheryl Xu | Common Stock | Buy | Acquire P | No | No | 0.375 | 200,000 | 75.00 k | 424,934 |
31 Jan 24 | Cheryl Xu | Warrant Common Stock | Buy | Acquire P | No | No | 0.01 | 200,000 | 2.00 k | 200,000 |
28 Jul 23 | Knight Therapeutics | Series A Non-Voting Convertible Preferred Stock | Conversion | Dispose C | Yes | No | 0 | 2,162 | 0.00 | 78,803 |
28 Jul 23 | Knight Therapeutics | Common Stock, $0.0001 par value per share ("Common Shares") | Conversion | Acquire C | Yes | No | 4.745 | 45,560 | 216.18 k | 1,153,897 |
12 Jul 23 | Geoffrey S Dow | NQSO Common Stock | Grant | Acquire A | No | No | 5.3 | 300,000 | 1.59 mm | 300,000 |
12 Jul 23 | Tyrone Miller | NQSO Common Stock | Grant | Acquire A | No | No | 5.3 | 240,000 | 1.27 mm | 240,000 |
News
HC Wainwright & Co. Reiterates Neutral on 60 Degrees
3 Apr 24
60 Degrees Q4 EPS $(0.44) Misses $(0.20) Estimate, Sales $125.68K Beat $70.00K Estimate
2 Apr 24
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
26 Mar 24
Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket
26 Mar 24
60 Degrees Pharmaceuticals Announces Communication From The FDA Of Intention To Respond To Tafenoquine-Babesiosis Trial Protocol Submission In April, 2024
14 Mar 24
Press releases
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
3 Apr 24
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
8 Feb 24
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
31 Jan 24
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
31 Jan 24
WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
30 Jan 24